{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:52:45Z","timestamp":1795035165903,"version":"4.10.2"},"reference-count":59,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["514473"],"award-info":[{"award-number":["514473"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["EV1-174804"],"award-info":[{"award-number":["EV1-174804"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2025,7,4]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Question<\/jats:title>\n                  <jats:p>What are the values and preferences of safer opioid supply clients?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study selection and analysis<\/jats:title>\n                  <jats:p>We conducted a systematic review of qualitative studies on safer opioid supply client experiences published between January 2016 and August 2024. Searches were conducted across seven databases\u2014MEDLINE, Embase, PsycINFO, CINAHL, EBM Reviews, Web of Science and Scopus\u2014and supplemented with searches in Google Scholar and relevant repositories. Study quality was assessed using the Critical Appraisal Skills Programme. Data analysis was guided by Thomas and Harden\u2019s thematic synthesis approach and confidence in review findings was evaluated using Grading of Recommendations Assessment, Development and Evaluation\u2013Confidence in the Evidence from Reviews of Qualitative research. The review was registered with PROSPERO (CRD42022384447).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>Our thematic synthesis included 19 peer-reviewed original research articles involving 459 study participants from British Columbia and Ontario, of whom 60.1% were men and 36.1% were women. Our findings centred on four cross-cutting analytic themes: (1) client-relevant goals and outcomes (withdrawal management, pain management, socioeconomic improvements), (2) the right medications to optimise client-relevant outcomes (multiple medication and formulation options, flexible dosage), (3) supportive, client-centred care environment (safe, welcoming and non-judgmental spaces, coordinating access to health and social support services, shared decision-making) and (4) complex adaptive systems approach to clinical policies (understanding the complexity of clients\u2019 living circumstances, flexible dose schedules, non-punitive policies). Confidence in findings ranged from moderate to high.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Safer opioid supply\u2019s success depends on providing individualised opioid medications, fostering person-centred care and implementing adaptive clinical policies. A supportive and flexible model enhances client satisfaction, sustains programme participation and optimises client-relevant outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjment-2025-301629","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:20:18Z","timestamp":1753438818000},"page":"e301629","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Safer opioid supply clients\u2019 values and preferences: a systematic review and thematic synthesis of qualitative research"],"prefix":"10.1136","volume":"28","author":[{"given":"Frishta","family":"Nafeh","sequence":"first","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Martignetti","sequence":"additional","affiliation":[{"name":"Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Kolla","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Memorial University, St. John\u2019s, Newfoundland and Labrador, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bonn","sequence":"additional","affiliation":[{"name":"Changemark Research & Evaluation, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahryar Moradi","family":"Falah Langeroodi","sequence":"additional","affiliation":[{"name":"Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Urbanoski","sequence":"additional","affiliation":[{"name":"Canadian Institute for Substance Use Research, University of Victoria, Victoria, British Columbia, Canada"},{"name":"Public Health and Social Policy, University of Victoria, Victoria, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernie","family":"Pauly","sequence":"additional","affiliation":[{"name":"Canadian Institute for Substance Use Research, University of Victoria, Victoria, British Columbia, Canada"},{"name":"School of Nursing, University of Victoria, Victoria, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Werb","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego School of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5631-4469","authenticated-orcid":false,"given":"Mohammad","family":"Karamouzian","sequence":"additional","affiliation":[{"name":"Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"HIV\/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2025082701501372000_28.1.e301629.1","unstructured":"Government of Canada . Opioid- and stimulant-related harms in Canada. Government of Canada. Available: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants [Accessed 3 Apr 2024]."},{"key":"2025082701501372000_28.1.e301629.2","unstructured":"Canadian Association of People who Use Drugs . Safe supply: concept document. Canadian association of people who use drugs. Available: https:\/\/vancouver.ca\/files\/cov\/capud-safe-supply-concept-document.pdf"},{"key":"2025082701501372000_28.1.e301629.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104339"},{"key":"2025082701501372000_28.1.e301629.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103742"},{"key":"2025082701501372000_28.1.e301629.5","doi-asserted-by":"crossref","first-page":"104157","DOI":"10.1016\/j.drugpo.2023.104157","article-title":"Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis","volume":"120","author":"Karamouzian","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2025082701501372000_28.1.e301629.6","doi-asserted-by":"crossref","first-page":"102769","DOI":"10.1016\/j.drugpo.2020.102769","article-title":"Tackling the overdose crisis: The role of safe supply","volume":"80","author":"Ivsins","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2025082701501372000_28.1.e301629.7","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"2025082701501372000_28.1.e301629.8","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20200021"},{"key":"2025082701501372000_28.1.e301629.9","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.190344"},{"key":"2025082701501372000_28.1.e301629.10","first-page":"1","article-title":"A Preliminary Assessment of Short-Term Social and Substance Use-Related Outcomes Among Clients of Integrated Safer Opioid Supply Pilot Programs in Toronto, Canada","volume":"2023","author":"Nafeh","year":"2023","journal-title":"Int J Ment Health Addiction"},{"key":"2025082701501372000_28.1.e301629.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076336","article-title":"Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study","volume":"384","author":"Slaunwhite","year":"2024","journal-title":"BMJ"},{"key":"2025082701501372000_28.1.e301629.12","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.220892"},{"key":"2025082701501372000_28.1.e301629.13","doi-asserted-by":"crossref","first-page":"104665","DOI":"10.1016\/j.drugpo.2024.104665","article-title":"Motivations for and perspectives of medication diversion among clients of a safer opioid supply program in Toronto, Canada","volume":"135","author":"Martignetti","year":"2025","journal-title":"Int J Drug Policy"},{"key":"2025082701501372000_28.1.e301629.14","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.241173"},{"key":"2025082701501372000_28.1.e301629.15","doi-asserted-by":"crossref","first-page":"104330","DOI":"10.1016\/j.drugpo.2024.104330","article-title":"The impact of an unsanctioned compassion club on non-fatal overdose","volume":"131","author":"Kalicum","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2025082701501372000_28.1.e301629.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.09.025"},{"key":"2025082701501372000_28.1.e301629.17","doi-asserted-by":"publisher","DOI":"10.1177\/1049732312452938"},{"key":"2025082701501372000_28.1.e301629.18","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1136\/bmjspcare-2021-003161","article-title":"SPIDER as a framework to formulate eligibility criteria in qualitative systematic reviews","volume":"14","author":"Amir-Behghadami","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"2025082701501372000_28.1.e301629.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025082701501372000_28.1.e301629.20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-181"},{"key":"2025082701501372000_28.1.e301629.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"2025082701501372000_28.1.e301629.22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/2632084320947559","article-title":"Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis","volume":"1","author":"Long","year":"2020","journal-title":"Research Methods in Medicine & Health Sciences"},{"key":"2025082701501372000_28.1.e301629.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2018-111132"},{"key":"2025082701501372000_28.1.e301629.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-8-45","article-title":"Methods for the thematic synthesis of qualitative research in systematic reviews","volume":"8","author":"Thomas","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"2025082701501372000_28.1.e301629.25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13012-017-0688-3","article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series","volume":"13","author":"Lewin","year":"2018","journal-title":"Implementation Sci"},{"key":"2025082701501372000_28.1.e301629.26","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0690-9"},{"key":"2025082701501372000_28.1.e301629.27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13012-017-0691-8","article-title":"Applying GRADE-CERQual to qualitative evidence synthesis findings\u2014paper 4: how to assess coherence","volume":"13","author":"Colvin","year":"2018","journal-title":"Implementation Sci"},{"key":"2025082701501372000_28.1.e301629.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0692-7"},{"key":"2025082701501372000_28.1.e301629.29","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0693-6"},{"key":"2025082701501372000_28.1.e301629.30","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.221550"},{"key":"2025082701501372000_28.1.e301629.31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12954-023-00817-7","article-title":"Impact of safer supply programs on injection practices: client and provider experiences in Ontario, Canada","volume":"20","author":"Gagnon","year":"2023","journal-title":"Harm Reduct J"},{"key":"2025082701501372000_28.1.e301629.32","doi-asserted-by":"crossref","first-page":"104023","DOI":"10.1016\/j.drugpo.2023.104023","article-title":"Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies","volume":"115","author":"Giang","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2025082701501372000_28.1.e301629.33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-023-00776-z","article-title":"Safer opioid supply: qualitative program evaluation","volume":"20","author":"Haines","year":"2023","journal-title":"Harm Reduct J"},{"key":"2025082701501372000_28.1.e301629.34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/00220426241231499","article-title":"Context of Substance Use: Harm Reduction and Safer Supply","volume":"55","author":"Haines","year":"2025","journal-title":"J Drug Issues"},{"key":"2025082701501372000_28.1.e301629.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299801","article-title":"'And this is the life jacket, the lifeline they\u2019ve been wanting': Participant perspectives on navigating challenges and successes of prescribed safer supply","volume":"19","author":"Henderson","year":"2024","journal-title":"PLoS One"},{"key":"2025082701501372000_28.1.e301629.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108202"},{"key":"2025082701501372000_28.1.e301629.37","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-020-00489-9"},{"key":"2025082701501372000_28.1.e301629.38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15288\/jsad.23-00388","article-title":"Reasons for Enrolling in Safer Supply Programs: A Longitudinal Qualitative Study on Participant Goals and Related Outcomes in the MySafe Program","volume":"85","author":"Ivsins","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"key":"2025082701501372000_28.1.e301629.39","doi-asserted-by":"crossref","first-page":"104601","DOI":"10.1016\/j.drugpo.2024.104601","article-title":"Repurposing prescribed hydromorphone: Alternative uses of safer supply and tablet-injectable opioid agonist treatment to meet unaddressed health needs","volume":"133","author":"Ivsins","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2025082701501372000_28.1.e301629.40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12954-024-01029-3","article-title":"'If it wasn\u2019t for them, I don\u2019t think I would be here': experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis","volume":"21","author":"Kolla","year":"2024","journal-title":"Harm Reduct J"},{"key":"2025082701501372000_28.1.e301629.41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12954-024-00935-w","article-title":"Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site","volume":"21","author":"Kolla","year":"2024","journal-title":"Harm Reduct J"},{"key":"2025082701501372000_28.1.e301629.42","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306692"},{"key":"2025082701501372000_28.1.e301629.43","doi-asserted-by":"crossref","first-page":"104547","DOI":"10.1016\/j.drugpo.2024.104547","article-title":"A qualitative evaluation of a fentanyl patch safer supply program in Vancouver, Canada","volume":"131","author":"Norton","year":"2024","journal-title":"International Journal of Drug Policy"},{"key":"2025082701501372000_28.1.e301629.44","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/dar.13745","article-title":"'I don\u2019t chase drugs as much anymore, and I\u2019m not dead': Client reported outcomes associated with safer opioid supply programs in Ontario, Canada","volume":"42","author":"Schmidt","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"2025082701501372000_28.1.e301629.45","doi-asserted-by":"crossref","first-page":"103849","DOI":"10.1016\/j.drugpo.2022.103849","article-title":"A concept mapping study of service user design of safer supply as an alternative to the illicit drug market","volume":"110","author":"Pauly","year":"2022","journal-title":"International Journal of Drug Policy"},{"key":"2025082701501372000_28.1.e301629.46","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-022-00679-7"},{"key":"2025082701501372000_28.1.e301629.47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13011-024-00625-7","article-title":"Access and barriers to safer supply prescribing during a toxic drug emergency: a mixed methods study of implementation in British Columbia, Canada","volume":"19","author":"Urbanoski","year":"2024","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025082701501372000_28.1.e301629.48","doi-asserted-by":"crossref","first-page":"116683","DOI":"10.1016\/j.socscimed.2024.116683","article-title":"'The machine doesn\u2019t judge': Counternarratives on surveillance among people accessing a safer opioid supply via biometric machines","volume":"345","author":"Bardwell","year":"2024","journal-title":"Soc Sci Med"},{"key":"2025082701501372000_28.1.e301629.49","unstructured":"Krotulski AJ , Papsum D , Walton SE , et al . New synthetic opioid protonitazene increasing in prevalence as 'nitazenes' gain traction across the United States and Canada. Center for Forensic Science Research and Education; 2021."},{"key":"2025082701501372000_28.1.e301629.50","doi-asserted-by":"crossref","first-page":"111777","DOI":"10.1016\/j.forsciint.2023.111777","article-title":"Fentanyl concentrations in ligated femoral blood in the presence and absence of NPS benzodiazepine drugs. A review of over 1250 benzo-dope \/ fentanyl toxicity cases in Alberta, Canada","volume":"350","author":"Chatterton","year":"2023","journal-title":"Forensic Sci Int"},{"key":"2025082701501372000_28.1.e301629.51","doi-asserted-by":"crossref","first-page":"104197","DOI":"10.1016\/j.drugpo.2023.104197","article-title":"Trends in varying modes of drug use in opioid toxicity deaths in Ontario from 2017 to 2021","volume":"141","author":"MacDonald","year":"2025","journal-title":"Int J Drug Policy"},{"key":"2025082701501372000_28.1.e301629.52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.15288\/jsad.2022.83.309","article-title":"More Than a Pipe Dream? The Need to Adapt Safer Opioid Supply Programs for People Who Smoke Drugs","volume":"83","author":"Bardwell","year":"2022","journal-title":"J Stud Alcohol Drugs"},{"key":"2025082701501372000_28.1.e301629.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111053"},{"key":"2025082701501372000_28.1.e301629.54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)","volume":"74","author":"Potter","year":"2013","journal-title":"J Stud Alcohol Drugs"},{"key":"2025082701501372000_28.1.e301629.55","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-023-00585-4","article-title":"Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)","volume":"19","author":"Beaumont","year":"2024","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025082701501372000_28.1.e301629.56","doi-asserted-by":"crossref","unstructured":"Power N , Archambault L , Perreault M . New Challenges and Opportunities for Opioid Agonist Treatment Access and Retention: A Scoping Review. J Drug Issues 2024. doi:10.1177\/00220426241269828","DOI":"10.1177\/00220426241269828"},{"key":"2025082701501372000_28.1.e301629.57","doi-asserted-by":"publisher","DOI":"10.1186\/s12961-020-00596-8"},{"key":"2025082701501372000_28.1.e301629.58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025082701501372000_28.1.e301629.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108374"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2025-301629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:50:29Z","timestamp":1756284629000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2025-301629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,25]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjment-2025-301629"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2025-301629","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}